Assessment of Drug–drug Interaction and Optimization in Capecitabine and Irinotecan Combination Regimen using a Physiologically Based Pharmacokinetic Model
-
Published:2021-12
Issue:
Volume:
Page:
-
ISSN:0022-3549
-
Container-title:Journal of Pharmaceutical Sciences
-
language:en
-
Short-container-title:Journal of Pharmaceutical Sciences
Author:
Sakai Shuhei,
Kobuchi ShinjiORCID,
Ito Yukako,
Sakaeda Toshiyuki
Subject
Pharmaceutical Science
Reference35 articles.
1. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer;Casssidy;J Clin Oncol,2008
2. Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial;Ducreux;Lancet Oncol,2011
3. XELOX vs. FOLFOX in metastatic colorectal cancer: an updated meta-analysis;Guo;Cancer Invest,2016
4. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial
5. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorourcil selectivity in tumors by enzymes concentrated in human liver and cancer tissue;Miwa;Eur J Cancer,1998
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献